Clinical Trial Update: Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, and pharmacokinetics of TBI-223 in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis
• Tuberculosis

Drugs mentioned

• TBI-223

Snippet

Sponsor: Global Alliance for TB Drug Development | Conditions: Tuberculosis, Tuberculosis, Pulmonary | Phase 1 | Status: COMPLETED